125 related articles for article (PubMed ID: 34049724)
1. Buprenorphine utilization among all Washington State residents' based upon prescription monitoring program data - Characteristics associated with two measures of retention and patterns of care over time.
Banta-Green CJ; Hansen RN; Ossiander EM; Wasserman CR; Merrill JO
J Subst Abuse Treat; 2021 Aug; 127():108446. PubMed ID: 34049724
[TBL] [Abstract][Full Text] [Related]
2. Non-buprenorphine opioid utilization among patients using buprenorphine.
Daubresse M; Saloner B; Pollack HA; Alexander GC
Addiction; 2017 Jun; 112(6):1045-1053. PubMed ID: 28107580
[TBL] [Abstract][Full Text] [Related]
3. The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State.
Banta-Green CJ; Owens MD; Williams JR; Sears JM; Floyd AS; Williams-Gilbert W; Kingston S
Addict Sci Clin Pract; 2022 Jul; 17(1):34. PubMed ID: 35799210
[TBL] [Abstract][Full Text] [Related]
4. Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration.
Manhapra A; Petrakis I; Rosenheck R
Am J Addict; 2017 Sep; 26(6):572-580. PubMed ID: 28472543
[TBL] [Abstract][Full Text] [Related]
5. Adherence to buprenorphine: An analysis of prescription drug monitoring program data.
Pizzicato LN; Hom JK; Sun M; Johnson CC; Viner KM
Drug Alcohol Depend; 2020 Nov; 216():108317. PubMed ID: 33035714
[TBL] [Abstract][Full Text] [Related]
6. Concomitant use of buprenorphine for medication-assisted treatment of opioid use disorder and benzodiazepines: Using the prescription behavior surveillance system.
Zhu Y; Coyle DT; Mohamoud M; Zhou E; Eworuke E; Dormitzer C; Staffa J
Drug Alcohol Depend; 2018 Jun; 187():221-226. PubMed ID: 29680678
[TBL] [Abstract][Full Text] [Related]
7. Association between opioid analgesic therapy and initiation of buprenorphine management: An analysis of prescription drug monitoring program data.
Alexandridis AA; Dasgupta N; Ringwalt CL; Rosamond WD; Chelminski PR; Marshall SW
PLoS One; 2020; 15(1):e0227350. PubMed ID: 31923197
[TBL] [Abstract][Full Text] [Related]
8. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.
Burns L; Gisev N; Larney S; Dobbins T; Gibson A; Kimber J; Larance B; Mattick RP; Butler T; Degenhardt L
Addiction; 2015 Apr; 110(4):646-55. PubMed ID: 25516077
[TBL] [Abstract][Full Text] [Related]
9. Sociodemographic and prescribing characteristics that impact long-term retention in buprenorphine treatment for opioid use disorder among a statewide population.
Hallowell BD; Chambers LC; Samuels EA; Bratberg J; McDonald J; Nitenson A; Onyejekwe C; Beaudoin FL
Drug Alcohol Depend; 2022 Dec; 241():109680. PubMed ID: 36335834
[TBL] [Abstract][Full Text] [Related]
10. Three-Year Retention in Buprenorphine Treatment for Opioid Use Disorder Among Privately Insured Adults.
Manhapra A; Agbese E; Leslie DL; Rosenheck RA
Psychiatr Serv; 2018 Jul; 69(7):768-776. PubMed ID: 29656707
[TBL] [Abstract][Full Text] [Related]
11. Does Prescription Length of Buprenorphine Influence Treatment Outcomes in Opioid Use Disorder? A Retrospective Cohort Study from North India.
Ghosh A; Mahintamani T; Kathiravan S; Swer SB; Basu D; Mattoo SK; B N S; Singh A
Subst Use Misuse; 2023; 58(12):1620-1624. PubMed ID: 37469041
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.
Samples H; Williams AR; Olfson M; Crystal S
J Subst Abuse Treat; 2018 Dec; 95():9-17. PubMed ID: 30352671
[TBL] [Abstract][Full Text] [Related]
13. Federal Impacts on Buprenorphine Prescribing in Washington State, 2012 to 2022.
Xiong F; Jetson J; Park C; Delcher C
Am J Public Health; 2024 Jul; 114(7):696-704. PubMed ID: 38696736
[No Abstract] [Full Text] [Related]
14. Oral buprenorphine utilization, concomitant benzodiazepines and opioid analgesics, and payment source: Trends from 2015 to 2019.
Ijioma SC; Chilcoat HD; DeVeaugh-Geiss AM
J Subst Use Addict Treat; 2023 Apr; 147():208980. PubMed ID: 36841074
[TBL] [Abstract][Full Text] [Related]
15. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine.
Park TW; Larochelle MR; Saitz R; Wang N; Bernson D; Walley AY
Addiction; 2020 May; 115(5):924-932. PubMed ID: 31916306
[TBL] [Abstract][Full Text] [Related]
16. Same-day vs. delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program.
Jakubowski A; Lu T; DiRenno F; Jadow B; Giovanniello A; Nahvi S; Cunningham C; Fox A
J Subst Abuse Treat; 2020 Dec; 119():108140. PubMed ID: 33138925
[TBL] [Abstract][Full Text] [Related]
17. Buprenorphine treatment episode duration, dosage, and concurrent prescribing of benzodiazepines and opioid analgesics: The effects of Medicaid prior authorization policies.
Landis RK; Opper I; Saloner B; Gordon AJ; Leslie DL; Sorbero M; Stein BD
Drug Alcohol Depend; 2022 Dec; 241():109669. PubMed ID: 36332589
[TBL] [Abstract][Full Text] [Related]
18. Treatment Persistence Among Insured Patients Newly Starting Buprenorphine/Naloxone for Opioid Use Disorder.
Shcherbakova N; Tereso G; Spain J; Roose RJ
Ann Pharmacother; 2018 May; 52(5):405-414. PubMed ID: 29302989
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
Dunn KE; Tompkins DA; Bigelow GE; Strain EC
JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
[TBL] [Abstract][Full Text] [Related]
20. Prescribing patterns of buprenorphine waivered physicians.
Thomas CP; Doyle E; Kreiner PW; Jones CM; Dubenitz J; Horan A; Stein BD
Drug Alcohol Depend; 2017 Dec; 181():213-218. PubMed ID: 29096292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
